Extended oral antibiotic prophylaxis eliminated UTIs after robot-assisted radical cystectomy procedures. Prophylactic ...

AstraZeneca (AZ) has announced that its Imfinzi (durvalumab)-based perioperative regimen has been approved by the European Commission (EC) to treat resectable muscle-invasive bladder cancer (MIBC).

AstraZeneca’s Imfinzi receives European approval to treat patients with resectable muscle-invasive bladder cancer: Cambridge, UK Saturday, July 5, 2025, 09:00 Hrs [IST] AstraZen ...

Cambridge: AstraZeneca has received approval for Imfinzi (durvalumab) in the European Union (EU) for the treatment of adult ...

The global oncology market, including breakthrough treatments, is experiencing substantial growth, with revenues projected to reach hundreds of billions of dollars in the coming years. Several factors ...

Manufacturing companies are particularly attentive to drugs designated as breakthrough therapies due to the accelerated market access and higher returns on investment. Breakthrough therapy drugs often ...

Madrid - Ghali Belkahia, a young Moroccan physician who excels in the demanding world of high-precision urological surgery, recently contributed to the success of an unprecedented medical advancement ...

Ghali Belkahia, a young Moroccan physician excelling in the demanding field of high-precision urological surgery, has ...

Approval based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death for the ...

Obesity in itself is not a contraindication to radical prostatectomy, but it remains a risk factor for poor overall survival. Although obesity increases the technical complexity of radical ...

Beat bladder cancer with early detection! Expert insights reveal how a multidisciplinary approach can improve treatment outcomes in India. Learn more about effective care.

Results from the SWOG S1011 and LEA trials show that extended pelvic lymph node dissection during radical cystectomy for muscle-invasive bladder cancer offers no survival benefit.